Alibaba Group Appoints Two Independent Directors with Enhanced Corporate Governance
15.9.2022 02:43:00 EEST | Business Wire | Press release
Alibaba Group Holding Limited (NYSE: BABA and HKEX: 9988, the “Company”) announces that Irene Yun-Lien Lee, Chairman of Hysan Development Company Limited, and Albert Kong Ping Ng, former Chairman of Ernst & Young China, were appointed as independent directors to the Company’s board, effective August 4, 2022. The new appointments demonstrate the Company’s commitment to corporate governance excellence and diversity at the board level.
Following these appointments, the Company’s board currently consists of twelve directors, including seven independent directors. The number of female board members increases to three.
“I am delighted to welcome Ms. Lee and Mr. Ng to the Alibaba board. The new independent board member appointments are part of Alibaba’s ongoing enhancement of our corporate governance. Irene and Albert are both respected leaders with invaluable understanding and experience in global markets including mainland China and Hong Kong. I believe Alibaba will greatly benefit from their insight, especially in light of our plans for dual-primary listing in Hong Kong to further broaden and diversify our investor base,” said Daniel Zhang, Chairman and Chief Executive Officer of Alibaba Group.
“Alibaba is one of the most exciting and innovative companies of this generation and I am honored to become its board member,” said Irene Yun-Lien Lee. “The focus of my career has been to create a deep connection with consumers by curating top of mind physical destinations, where people come to work, shop and play. I am delighted to join Alibaba, with its mission to make it easier to do business with anyone, anywhere.”
“I am thrilled to join the board of a company with such a distinguished combination of Chinese origin and a global vision,” said Albert Ng. “as Alibaba applies to add Hong Kong as another primary listing venue, I hope my experiences in the capital market of Hong Kong and Greater China can be applied to the company's pursuit of excellence.”
Mr. Chee Hwa Tung, an independent director of the Company, will not seek re-election after his current term, which will end at the Company’s annual shareholding meeting to be held later this year. Mr. Tung has served as an independent director on the Company’s board since September 2014.
“We would like to express our most sincere gratitude to Mr. Tung for his invaluable contributions and full support to Alibaba, which exemplified the highest standards of service and commitment,” said Zhang.
About Irene Lee
Irene Lee has been executive chairman of Hysan Development Company Limited, a company listed on the Hong Kong Stock Exchange, since March 2012. Before that she was Hysan’s non-executive chairman from May 2011 to March 2012, and non-executive director from March 2011 to May 2011. Ms. Lee currently serves as the independent non-executive chairman of Hang Seng Bank Limited, a company listed on the Hong Kong Stock Exchange. She also serves as a director of various private and unlisted companies. Previously, Ms. Lee was an executive director of Citicorp Investment Bank Limited in New York, London and Sydney, and head of corporate finance at Commonwealth Bank of Australia and chief executive officer of Sealcorp Holdings Limited, both based in Sydney. In addition, she was until April 2022 an independent director of HSBC Holdings plc, and also previously served as director of a number of public companies. Ms. Lee received a bachelor of arts degree from Smith College, and is barrister-at-law in England and Wales and a member of the Honourable Society of Gray’s Inn, United Kingdom.
About Albert Ng
Albert Ng currently serves as an independent non-executive director and chairman of the audit committee of a number of public companies, including Ping An Insurance (Group) Company of China, Ltd., a company listed on the Shanghai Stock Exchange and the Hong Kong Stock Exchange, Beijing Airdoc Technology Co., Ltd., a company listed on the Hong Kong Stock Exchange, and China International Capital Corporation Limited, a company listed on the Shanghai Stock Exchange and the Hong Kong Stock Exchange. Mr. Ng worked at Ernst & Young China from April 2007 to June 2020, where he was the chairman of Ernst & Young China and a member of Ernst & Young’s Global Executive Board. Prior to joining Ernst & Young, he was Greater China Managing Partner of Arthur Andersen, Managing Partner – China Operation of PricewaterhouseCoopers and Managing Director of Citigroup – China Investment Banking. Mr. Ng is the president of the Hong Kong China Chamber of Commerce. Mr. Ng is also a member of the audit committee of The Chinese University of Hong Kong, Shenzhen, and a council member of the Education Foundation of The Chinese University of Hong Kong, Shenzhen. Mr. Ng is a member of the Hong Kong Institute of Certified Public Accountants (HKICPA), Chartered Accountants of Australia and New Zealand (CAANZ), CPA Australia (CPAA) and Association of Chartered Certified Accountants (ACCA). He received a bachelor’s degree in business administration and a master’s degree in business administration from The Chinese University of Hong Kong.
About Alibaba Group
Alibaba Group’s mission is to make it easy to do business anywhere. The company aims to build the future infrastructure of commerce. It envisions that its customers will meet, work and live at Alibaba, and that it will be a good company that lasts for 102 years.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220803006055/en/
Contact information
Media Contacts
Cathy Yan
Alibaba Group
+852 9012 5806
cathy.yan@alibaba-inc.com
Ivy Ke
Alibaba Group
+852 5590 9949
ivy.ke@alibaba-inc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AB InBev Reports First Quarter 2026 Results5.5.2026 08:02:00 EEST | Press release
Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504526109/en/ Regulated information1 “Cheers to beer - the strength of the category and the consistent execution of our consumer-centric strategy drove continued momentum across our footprint. We are investing behind our megabrands and innovations to lead and grow the category. With strong execution by our teams and major moments of celebration ahead, we are well positioned for 2026.” – Michel Doukeris, CEO, AB InBev Revenue +5.8% Revenue increased by 5.8% with revenue per hl growth of 4.5%. Reported revenue increased by 12.0% to 15 267 million USD, positively impacted by currency translation. 8.2% increase in combined revenues of megabrands, led by Corona, which grew by 16% outside of its home market. 27% increase in revenue of no-alcohol beer. 37% increase in revenue of Beyond Beer. 55% increase in Gross Mer
Kerecis Drives the Fish-Skin Conversation at Leading European Wound Conference - EWMA-DEWU 20264.5.2026 21:25:00 EEST | Press release
Kerecis, the company pioneering the use of sustainably sourced intact fish skin in cellular therapy and tissue regeneration, will play a prominent scientific and educational role at the EWMA‑DEWU 2026 Conference, taking place May 6–8 at the Messe & Congress Centrum Bremen in Bremen, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504487743/en/ MariCell® Solid This year, The European Wound Management Association's (EWMA) meeting is held in conjunction with the Deutscher Wundkongress (DEWU); combining two major wound-care congresses into a single forum for scientific exchange, education, and clinical discussion. At this year’s conference, Kerecis will highlight growing clinical experience with intact fish‑skin grafts across a broad range of wound indications, supported by two Kerecis‑led scientific symposia, multiple oral and poster presentations, and direct engagement with clinicians at Booth D30, located adjacent
Printing the Future of Medicine: CTIBIOTECH™ Announces $27 Million Investment to Launch U.S. Operations at the SelectUSA Investment Summit4.5.2026 21:00:00 EEST | Press release
CTIBIOTECH™, a pioneering Contract Research, Development, and Manufacturing Organization (CRDMO) and global leader in 3D bioprinting of human tissues, today officially announces the launch of its North American subsidiary, CTIBIOTECH USA™. The official launch took place today at the prestigious SelectUSA Investment Summit in Washington, D.C. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504107996/en/ From Biopsy to Breakthrough, CTIBIOTECH USA™'s Vision for Precision Medicine Operating from its new United States base in the thriving life sciences “Cellicon Valley” hub of Philadelphia, Pennsylvania, in association with BioLabs for Advanced Therapeutics, CTIBIOTECH USA™ will provide the company's proprietary human cell and tissue bioassays and New Approach Methods (NAMs) directly to North American pharmaceutical, biomedical, and dermatocosmetics markets. By producing and supplying these cutting-edge human bioassays domesti
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 18:16:00 EEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 17:28:00 EEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
